ResearcherKobe University HospitalActive in the last 2 years

Yoshiaki Nagatani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-6153-6456; OpenAlex author ID A5049081491. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 1 paper

Papers 1

Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase I… Co-author DOI 10.1016/j.ejca.2026.117034 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hisateru Yasui · 1 shared paper, 2026 · strength 0.24
- Paper Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced … DOI 10.1016/j.ejca.2026.117034 ↗
Hironobu Minami · 1 shared paper, 2026 · strength 0.24
- Paper Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced … DOI 10.1016/j.ejca.2026.117034 ↗
Hirochika Toyama · 1 shared paper, 2026 · strength 0.24
- Paper Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced … DOI 10.1016/j.ejca.2026.117034 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.